drugset / Trial / NCT06706219
Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC
NaSingle-groupOpen-labelTreatment
Summary
This study is a phase 2 open-label, single-center clinical study to evaluate the efficacy and safety SKB264 in combination with toripalimab in patients with unresectable stage III non-small cell lung cancer
Timeline
- Start
- 2026-05-10
- Primary completion
- 2028-11-30
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sacituzumab Tirumotecan | Other / unclassified | 4 mg/kg | Intravenous |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |